Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: Results from a randomised multicentre trial (ENRADAS)

Annals of the Rheumatic Diseases

Volumn 75, Issue 8, 2016, Pages 1438-1443

  Sieper, Joachim ^a,b   Listing, Joachim ^b   Poddubnyy, Denis ^a   Song, In Ho ^a,c   Hermann, Kay Geert ^a   Callhoff, Johanna ^b   Syrbe, Uta ^a   Braun, Jürgen ^d   Rudwaleit, Martin ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Rheumatology Research Center   (Germany)

^c ABBVIE INC   (United States)

^d RHEUMAZENTRUM RUHRGEBIET   (Germany)

^e Klinikum Bielefeld   (Germany)

Author keywords

Ankylosing Spondylitis; NSAIDs; Outcomes research

Indexed keywords

C REACTIVE PROTEIN; DICLOFENAC; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE PANCREATITIS; ADULT; ANGINA PECTORIS; ANKYLOSING SPONDYLITIS; ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE COURSE; DIVERTICULOSIS; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; INGUINAL HERNIA; MAJOR CLINICAL STUDY; MALE; MODIFIED STOKE ANKYLOSING SPONDYLITIS SPINE SCORE; MULTICENTER STUDY; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SPINE DISEASE; SPINE RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; URETER STONE; WOLFF PARKINSON WHITE SYNDROME; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; MIDDLE AGED; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; SINGLE BLIND PROCEDURE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84940194212     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207897     Document Type: Article

References (29)

1. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis ( part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
2. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
3. Machado P, Landewe R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;69:1465-70.
4. Landewe R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68:863-7.
5. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
6. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-54.
7. Baraliakos X, Haibel H, Listing J, et al. Continuous long-Term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-15.
8. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
9. Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 1976;5:60-4.
10. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
11. Dougados M, Simon P, Braun J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70:249-51.
12. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616-22.
13. van der Heijde D, Landewe R. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. J Rheumatol 2005;32:2048-9.
14. Brunner E, Domhof S, Langer F. Nonparametric analysis of longitudinal data in factorial designs. New York: Wiley, 2002.
15. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-15.
16. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388-98.
17. Kroon F, Landewe R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:1623-9.
18. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
19. Vane SJ. Differential inhibition of cyclooxygenase isoforms: An explanation of the action of NSAIDs. J Clin Rheumatol 1998;4(5 Suppl):s3-10.
20. Krischak GD, Augat P, Blakytny R, et al. The non-steroidal anti-inflammatory drug diclofenac reduces appearance of osteoblasts in bone defect healing in rats. Arch Orthop Trauma Surg 2007;127:453-8.
21. Simon AM, Manigrasso MB, OConnor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-76.
22. Romano CL, Duci D, Romano D, et al. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty 2004;19:14-18.
23. Saudan M, Saudan P, Perneger T, et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: A prospective randomised trial. J Bone Joint Surg Br 2007;89:155-9.
24. Zweers MC, de Boer TN, van Roon J, et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther 2011;13:239.
25. Mastbergen SC, Jansen NW, Bijlsma JW, et al. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: An in vitro study. Arthritis Res Ther 2006;8:R2.
26. Chang JK, Li CJ, Liao HJ, et al. Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-Apoptotic factors in cultured human osteoblasts. Toxicology 2009;258:148-56.
27. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-72.
28. Schonthal AH. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 2007;97:1465-8.
29. Song IH, Poddubnyy DA, Rudwaleit M, et al. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008;58:929-38.